etiology, effects and treatment. CMAJ. 2007 Apr 10;176(8):1113-20. \[[PMC free article: PMC1839776](/pmc/articles/PMC1839776/)\] \[[PubMed: 17420495](https://pubmed.ncbi.nlm.nih.gov/17420495)\] 8. Blackett P, Tryggestad J, Krishnan S, Li S, Xu W, Alaupovic P, Quiroga C, Copeland K. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J Clin Lipidol. 2013 Mar-Apr;7(2):132-9. \[[PubMed: 23415432](https://pubmed.ncbi.nlm.nih.gov/23415432)\] 9. Okopień B, Bułdak Ł, Bołdys A. Benefits and risks of the treatment with fibrates--a comprehensive summary. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1099-1112. \[[PubMed: 30328735](https://pubmed.ncbi.nlm.nih.gov/30328735)\] 10. Kobayashi J, Mabuchi H. Lipoprotein lipase and atherosclerosis. Ann Clin Biochem. 2015 Nov;52(Pt 6):632-7. \[[PubMed: 25995285](https://pubmed.ncbi.nlm.nih.gov/25995285)\] **Disclosure:** Yasaman Pirahanchi declares no relevant financial relationships with ineligible companies. **Disclosure:** McDamian Anoruo declares no relevant financial relationships with ineligible companies. **Disclosure:** Sandeep Sharma declares no relevant financial relationships with ineligible companies.